Multicenter cohort shows that tildrakizumab effectively improves moderate-to-severe psoriasis, indicating it is a reliable treatment option.
Tildrakizumab demonstrated high effectiveness and a favorable safety profile in this large, real-world multicenter cohort. These findings support its role as a reliable therapeutic option for patients with moderate-to-severe plaque psoriasis in clinical practice.
No takes yet. Share an insight, caveat, or question.
Izu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: